NASDAQ: EVOKEvoke Pharma Inc Stock Ownership - Who owns Evoke Pharma?
Insider buying vs selling
Have Evoke Pharma Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Matthew J. Donofrio | Chief Executive Officer | 2025-03-21 | 1,000 | $2.80 | $2.80kBuy |
| Mark Kowieski | Chief Financial Officer | 2025-03-20 | 4,500 | $3.21 | $14.46kBuy |
| Matthew J. Donofrio | Chief Executive Officer | 2025-02-28 | 6,849 | $3.65 | $25.00kBuy |
| Nantahala Capital Management LLC | 10% Owner | 2025-01-28 | 41 | $4.39 | $179.87Sell |
EVOK insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when EVOK insiders and whales buy or sell their stock.
EVOK Shareholders
What type of owners hold Evoke Pharma Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Lvp GP III LLC | 134.02% | 2,088,579 | $10.76M | Insider |
| Kenneth J. Widder | 101.93% | 1,588,579 | $8.18M | Insider |
| Jesse I. Treu | 73.06% | 1,138,583 | $5.86M | Insider |
| Kathleen K. Schoemaker | 73.06% | 1,138,583 | $5.86M | Insider |
| Nicole Vitullo | 73.06% | 1,138,583 | $5.86M | Insider |
| James C. Blair | 73.06% | 1,138,583 | $5.86M | Insider |
| Brian K. Halak | 73.06% | 1,138,583 | $5.86M | Insider |
| Brian H. Dovey | 73.06% | 1,138,583 | $5.86M | Insider |
| Domain Parters VII L P | 38.90% | 606,283 | $3.12M | Insider |
| David A. Gonyer | 21.80% | 339,782 | $1.75M | Insider |
EVOK vs Pharmaceutical Stocks
Evoke Pharma Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.